Integrated Investment Consultants LLC Buys New Holdings in Cencora, Inc. (NYSE:COR)

Integrated Investment Consultants LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,731 shares of the company’s stock, valued at approximately $4,216,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Osaic Holdings Inc. purchased a new stake in shares of Cencora in the first quarter worth about $9,962,000. Covestor Ltd purchased a new stake in Cencora in the 1st quarter worth approximately $55,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Cencora during the 1st quarter worth approximately $465,000. American International Group Inc. purchased a new position in shares of Cencora during the 1st quarter valued at approximately $10,872,000. Finally, InterOcean Capital Group LLC acquired a new position in shares of Cencora in the 1st quarter valued at $251,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.9 %

Shares of COR opened at $243.20 on Thursday. Cencora, Inc. has a 52-week low of $195.83 and a 52-week high of $251.56. The stock has a market cap of $47.92 billion, a PE ratio of 32.38, a price-to-earnings-growth ratio of 1.60 and a beta of 0.44. The firm’s fifty day moving average is $232.82 and its two-hundred day moving average is $231.29. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be issued a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.90%. Cencora’s dividend payout ratio is presently 29.29%.

Analyst Ratings Changes

A number of research firms have weighed in on COR. UBS Group lifted their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Leerink Partners dropped their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Finally, Evercore ISI lifted their price target on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $271.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.